Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308–18.

Article  PubMed  CAS  Google Scholar 

Charras A, Smith E, Hedrich CM. Systemic lupus erythematosus in children and young people. Curr Rheumatol Rep. 2021;23(3):20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252–62.

Article  PubMed  Google Scholar 

Ardoin SP, Daly RP, Merzoug L, Tse K, Ardalan K, Arkin L, et al. Research priorities in childhood-onset lupus: results of a multidisciplinary prioritization exercise. Pediatr Rheumatol Online J. 2019;17(1):32.

Article  PubMed  PubMed Central  Google Scholar 

Oni L, Wright RD, Marks S, Beresford MW, Tullus K. Kidney outcomes for children with lupus nephritis. Pediatr Nephrol. 2021;36(6):1377–85.

Article  PubMed  Google Scholar 

Pinheiro SVB, Dias RF, Fabiano RCG, Araujo SA, Silva A. Pediatric lupus nephritis. J Bras Nefrol. 2019;41(2):252–65.

Article  PubMed  Google Scholar 

Suhlrie A, Hennies I, Gellermann J, Büscher A, Hoyer P, Waldegger S, et al. Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study. Pediatr Nephrol. 2020;35(7):1235–46.

Article  PubMed  Google Scholar 

GSK. Benlysta prescribing information. 2022. Available from: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF. Accessed 24 Jan 2023.

Levy RA, Gonzalez-Rivera T, Khamashta M, Fox NL, Jones-Leone A, Rubin B, et al. 10 Years of belimumab experience: what have we learnt? Lupus. 2021;30(11):1705–21.

Article  PubMed  PubMed Central  CAS  Google Scholar 

GSK. China’s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis. 2022. https://www.gsk.com/en-gb/media/press-releases/china-s-national-medical-productsadministration-approves-benlysta-belimumab-for-adult-patients-with-active-lupus-nephritis/. Accessed 17 Sep 2024.

Sada K, Kurita N, Noma H, Matsuki T, Quasny H, Levy RA, et al. MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT. Lupus Sci Med. 2022;9(1): e000746.

Article  PubMed  PubMed Central  Google Scholar 

Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–65.

Article  PubMed  CAS  Google Scholar 

Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166(1):6–10.

Article  PubMed  CAS  Google Scholar 

Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31.

Article  PubMed  CAS  Google Scholar 

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–28.

Article  PubMed  CAS  Google Scholar 

Struemper H, Chen C, Cai W. Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. J Clin Pharmacol. 2013;53(7):711–20.

Article  PubMed  Google Scholar 

Dimelow R, Ji B, Struemper H. Pharmacokinetics of belimumab in children with systemic lupus erythematosus. Clin Pharmacol Drug Dev. 2021;10(6):622–33.

Article  PubMed  CAS  Google Scholar 

Simeoni M, Yang S, Tompson DJ, Dimelow R. Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. J Pharmacokinet Pharmacodyn. 2024;51(3):289–301.

Hiraki LT, Feldman CH, Liu J, Alarcón GS, Fischer MA, Winkelmayer WC, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64(8):2669–76.

Article  PubMed  PubMed Central  Google Scholar 

Demir S, Gülhan B, Özen S, Çeleğen K, Batu ED, Taş N, et al. Long-term renal survival of paediatric patients with lupus nephritis. Nephrol Dial Transplant. 2022;37(6):1069–77.

Article  PubMed  CAS  Google Scholar 

US Food and Drug Administration. General clinical pharmacology considerations for pediatric studies of drugs, including biological products: guidance for industry. Silver Spring, Maryland; 2022.

Balevic SJ, Niu J, Chen J, Green D, McMahon A, Hornik CP, et al. Extrapolation of adult efficacy data to pediatric systemic lupus erythematosus: evaluating similarities in exposure-response. J Clin Pharmacol. 2023;63(1):105–18.

Article  PubMed  CAS  Google Scholar 

Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340–8.

Article  PubMed  CAS  Google Scholar 

Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.

Article  PubMed  Google Scholar 

Izmirly PM, Wan I, Sahl S, Buyon JP, Belmont HM, Salmon JE, et al. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: the Manhattan Lupus Surveillance Program. Arthritis Rheumatol. 2017;69(10):2006–17.

Article  PubMed  PubMed Central  Google Scholar 

Livingston B, Bonner A, Pope J. Differences in autoantibody profiles and disease activity and damage scores between childhood- and adult-onset systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2012;42(3):271–80.

Article  PubMed  CAS  Google Scholar 

Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis. 2015;18(2):182–91.

Article  PubMed  Google Scholar 

Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–35.

Article  PubMed  Google Scholar 

Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):556–62.

Article  PubMed  Google Scholar 

Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017;76(12):1965–73.

Article  PubMed  CAS  Google Scholar 

Momtaz M, Fayed A, Wadie M, Gamal SM, Ghoniem SA, Sobhy N, et al. Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience. Lupus. 2017;26(14):1564–70.

Article  PubMed  CAS  Google Scholar 

Papadimitraki ED, Isenberg DA. Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol. 2009;5(4):391–403.

Article  PubMed  Google Scholar 

Ruggiero B, Vivarelli M, Gianviti A, Benetti E, Peruzzi L, Barbano G, et al. Lupus nephritis in children and adolescents: results of the Italian Collaborative Study. Nephrol Dial Transplant. 2013;28(6):1487–96.